Nuvation Bio Inc. Equity Securities, FV-NI, Gain (Loss)
Nuvation Bio Inc. (NUVB) reported Equity Securities, FV-NI, Gain (Loss) of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-29.
Discontinued › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiGainLoss · last filed 2024-02-29
- Nuvation Bio Inc. equity securities, fv-ni, gain (loss) for the quarter ending 2023-12-31 was $0.00.
- Nuvation Bio Inc. equity securities, fv-ni, gain (loss) for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Nuvation Bio Inc. equity securities, fv-ni, gain (loss) for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Nuvation Bio Inc. equity securities, fv-ni, gain (loss) for the quarter ending 2023-03-31 was $0.00.
- Nuvation Bio Inc. equity securities, fv-ni, gain (loss) for fiscal 2023 was $0.00.
- Nuvation Bio Inc. equity securities, fv-ni, gain (loss) for fiscal 2022 was -$172.00K.
- Nuvation Bio Inc. equity securities, fv-ni, gain (loss) for fiscal 2021 was -$166.00K.
| Period end | Equity Securities, FV-NI, Gain (Loss) 3 month | Equity Securities, FV-NI, Gain (Loss) 3 month as first filed | Equity Securities, FV-NI, Gain (Loss) 6 month | Equity Securities, FV-NI, Gain (Loss) 9 month | Equity Securities, FV-NI, Gain (Loss) 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $0.00 derived: sum of 3 quarters · filed 2024-02-29 | $0.00 10-K · filed 2024-02-29 | |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-02 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | -$1.00K derived: sum of 4 quarters · filed 2024-02-29 | |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 | -$1.00K derived: sum of 3 quarters · filed 2024-02-29 | $0.00 derived: sum of 4 quarters · filed 2024-02-29 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 | -$1.00K derived: sum of 2 quarters · filed 2024-02-29 | $0.00 derived: sum of 3 quarters · filed 2024-02-29 | $1.00K derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $1.00K derived: sum of 3 quarters · filed 2024-02-29 | -$172.00K 10-K · filed 2024-02-29 | |
| 2022-09-30 | $1.00K 10-Q · filed 2023-11-02 | $2.00K derived: sum of 2 quarters · filed 2023-11-02 | -$171.00K 10-Q · filed 2023-11-02 | -$335.00K derived: sum of 4 quarters · filed 2023-11-02 | |
| 2022-06-30 | $1.00K 10-Q · filed 2023-08-03 | -$1.00K 10-Q · filed 2022-08-04 | -$172.00K 10-Q · filed 2023-08-03 | -$336.00K derived: sum of 3 quarters · filed 2023-08-03 | -$336.00K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$171.00K 10-Q · filed 2023-05-04 | -$337.00K derived: sum of 2 quarters · filed 2023-05-04 | -$337.00K derived: sum of 3 quarters · filed 2023-05-04 | -$337.00K derived: sum of 4 quarters · filed 2023-05-04 | |
| 2021-12-31 | -$166.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$166.00K derived: sum of 2 quarters · filed 2023-03-15 | -$166.00K derived: sum of 3 quarters · filed 2023-03-15 | -$166.00K 10-K · filed 2023-03-15 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-04 | $0.00 derived: sum of 2 quarters · filed 2022-08-04 | |||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |